^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CD19/CD22 CAR-T cell therapy
i
Other names: CD19/CD22 CAR-T cell therapy, CD19/CD22 chimeric antigen receptor T-cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shanghai Yake Biotech
Drug class:
CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
1m
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL (clinicaltrials.gov)
P2, N=28, Completed, Zhejiang University | Recruiting --> Completed | Phase classification: P1/2 --> P2 | N=50 --> 28 | Trial completion date: Mar 2025 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
Trial completion • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
CD19/CD22 CAR-T cell therapy
1year
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. (PubMed, Lancet Oncol)
This sequential strategy induced deep and sustained responses with an acceptable toxicity profile, and thus potentially provides long-term benefits for children with this condition.
P2 data • Clinical Trial,Phase II • Journal • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD19/CD22 CAR-T cell therapy • anti-CD22 CAR-T cell therapy
1year
Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults (ASH 2023)
Dasatinib in combination with a two-week vincristine and glucocorticoids regimen were administered, followed by sequential infusions of CD19 and CD22 CAR-T cells. Conclusions Dasatinib in combination with CAR-T cell therapy has enabled chemotherapy-free treatment in newly diagnosed Ph-positive ALL. This treatment is characterized by high complete molecular response, high long-term survival, low toxicity and short treatment cycles.
Clinical • CAR T-Cell Therapy • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • CD22 (CD22 Molecule)
|
BCR-ABL1 F317L • BCR-ABL1 Y253H • ABL1 F317L • ABL1 Y253H
|
dasatinib • vincristine • CD19/CD22 CAR-T cell therapy • anti-CD22 CAR-T cell therapy
over3years
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL (clinicaltrials.gov)
P1/2, N=50, Recruiting, Zhejiang University
Clinical • New P1/2 trial
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
CD19/CD22 CAR-T cell therapy
almost4years
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL (clinicaltrials.gov)
P1/2, N=50, Recruiting, Zhejiang University
Clinical • New P1/2 trial
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD22 positive
|
CD19/CD22 CAR-T cell therapy
Share via
